Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia
Launched by PFIZER · Sep 7, 2005
Trial Information
Current as of May 04, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients must have pain present for more than 3 months after the healing of shingles skin rash.
- • Patients at screening must have a score \>=40 mm on the pain visual analogue scale.
- Exclusion Criteria:
- • Patients with poor renal function.
- • Patients with other severe pain, that may impair the self-assessment of the pain due to shingles.
- • Patients with abnormal electrocardiogram.
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
, ,
Halifax, Nova Scotia, Canada
Toronto, Ontario, Canada
Praha 5, , Czech Republic
Barcelona, , Spain
Madrid, , Spain
London, , United Kingdom
Rotterdam, , Netherlands
Bedford Park, South Australia, Australia
Sherbrooke, Quebec, Canada
Ste Foy, Quebec, Canada
Arnhem, , Netherlands
Breda, , Netherlands
Granada, , Spain
Malaga, , Spain
Sevilla, , Spain
Brno, , Czech Republic
Kelowna, British Columbia, Canada
Warrawong, New South Wales, Australia
Westmead, New South Wales, Australia
Kippa Ring, Queensland, Australia
Maroochydore, Queensland, Australia
Perth, Western Australia, Australia
Woodville, , Australia
Ceske Budejovice, , Czech Republic
Cz Praha 8, , Czech Republic
Plzen, , Czech Republic
Kampen, , Netherlands
Roosendaal, , Netherlands
Stadskanaal, , Netherlands
Portsmouth, Hants, United Kingdom
Northampton, Northants, United Kingdom
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials